This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Su, G. H. Articles by Kern, S. E. Search for Related Content PubMed PubMed Citation Articles by Su, G. H. Articles by Kern, S. E.

A Novel Histone Deacetylase Inhibitor Identified by High-Throughput Transcriptional Screening of a Compound Library¹

Departments of Pathology [G. H. S.] and Surgery [T. A. S.] and The Oncology Center [G. H. S., B. R., S. E. K.], The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205-2196

Libraries of compounds are increasingly becoming commercially available for the use of individual academic laboratories. A high-throughput system based on a stably integrated transcriptional reporter was used to screen a library of random compounds to identify agents that conferred robust augmentation of a signal transduction pathway. A novel histone deacetylase (HDAC) inhibitor, termed scriptaid, conferred the greatest effect, a 12- to 18-fold augmentation. This facilitation of transcriptional events was generally applicable to exogenous gene constructs, including viral and cellular promoters, different cell lines and reporter genes, and stably integrated and transiently introduced sequences. Scriptaid did not interfere with a further induction provided by stimulation of the cognate signal transduction pathway (transforming growth factor ß/Smad4), which implied the functional independence of ligand-stimulated transcriptional activation and histone acetylation states in this system. Additional insights into this and other signal transduction systems are likely to be afforded through the application of compound screening technologies.

This article has been cited by other articles:

				S. L. McGee, B. J.W. van Denderen, K. F. Howlett, J. Mollica, J. D. Schertzer, B. E. Kemp, and M. Hargreaves AMP-Activated Protein Kinase Regulates GLUT4 Transcription by Phosphorylating Histone Deacetylase 5 Diabetes, April 1, 2008; 57(4): 860 - 867. [Abstract] [Full Text] [PDF]

				B. Langley, M. A. D'Annibale, K. Suh, I. Ayoub, A. Tolhurst, B. Bastan, L. Yang, B. Ko, M. Fisher, S. Cho, et al. Pulse Inhibition of Histone Deacetylases Induces Complete Resistance to Oxidative Death in Cortical Neurons without Toxicity and Reveals a Role for Cytoplasmic p21waf1/cip1 in Cell Cycle-Independent Neuroprotection J. Neurosci., January 2, 2008; 28(1): 163 - 176. [Abstract] [Full Text] [PDF]

				S. Inoue, A. Mai, M. J.S. Dyer, and G. M. Cohen Inhibition of Histone Deacetylase Class I but not Class II Is Critical for the Sensitization of Leukemic Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis. Cancer Res., July 1, 2006; 66(13): 6785 - 6792. [Abstract] [Full Text] [PDF]

				M. R. Acharya, A. Sparreboom, J. Venitz, and W. D. Figg Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review Mol. Pharmacol., October 1, 2005; 68(4): 917 - 932. [Abstract] [Full Text] [PDF]

				E. Gallmeier, J. M. Winter, S. C. Cunningham, S. R. Kahn, and S. E. Kern Novel genotoxicity assays identify norethindrone to activate p53 and phosphorylate H2AX Carcinogenesis, October 1, 2005; 26(10): 1811 - 1820. [Abstract] [Full Text] [PDF]

				B. Bartling, H.-S. Hofmann, B. Weigle, R.-E. Silber, and A. Simm Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma Carcinogenesis, February 1, 2005; 26(2): 293 - 301. [Abstract] [Full Text] [PDF]

				H.-M. Chang, M. Paulson, M. Holko, C. M. Rice, B. R. G. Williams, I. Marie, and D. E. Levy Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity PNAS, June 29, 2004; 101(26): 9578 - 9583. [Abstract] [Full Text] [PDF]

				H. Cao, G. Stamatoyannopoulos, and M. Jung Induction of human {gamma} globin gene expression by histone deacetylase inhibitors Blood, January 15, 2004; 103(2): 701 - 709. [Abstract] [Full Text] [PDF]

				E. Hu, E. Dul, C.-M. Sung, Z. Chen, R. Kirkpatrick, G.-F. Zhang, K. Johanson, R. Liu, A. Lago, G. Hofmann, et al. Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 720 - 728. [Abstract] [Full Text] [PDF]

				K. B. Glaser, J. Li, M. E. Aakre, D. W. Morgan, G. Sheppard, K. D. Stewart, J. Pollock, P. Lee, C. Z. O'Connor, S. N. Anderson, et al. Transforming Growth Factor {beta} Mimetics: Discovery of 7-[4-(4-Cyanophenyl)phenoxy]-Heptanohydroxamic Acid, a Biaryl Hydroxamate Inhibitor of Histone Deacetylase Mol. Cancer Ther., August 1, 2002; 1(10): 759 - 768. [Abstract] [Full Text] [PDF]

				T. A. Sohn, R. Bansal, G. H. Su, K. M. Murphy, and S. E. Kern High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter Carcinogenesis, June 1, 2002; 23(6): 949 - 958. [Abstract] [Full Text] [PDF]

				G. H. Su, R. Bansal, K. M. Murphy, E. Montgomery, C. J. Yeo, R. H. Hruban, and S. E. Kern ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma PNAS, March 13, 2001; 98(6): 3254 - 3257. [Abstract] [Full Text] [PDF]